JP2015522522A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522522A5
JP2015522522A5 JP2015503431A JP2015503431A JP2015522522A5 JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5 JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015503431 A JP2015503431 A JP 2015503431A JP 2015522522 A5 JP2015522522 A5 JP 2015522522A5
Authority
JP
Japan
Prior art keywords
drug
prevent
relapse
nicotine
nicotine antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/033703 external-priority patent/WO2013148572A1/en
Publication of JP2015522522A publication Critical patent/JP2015522522A/ja
Publication of JP2015522522A5 publication Critical patent/JP2015522522A5/ja
Pending legal-status Critical Current

Links

JP2015503431A 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止 Pending JP2015522522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615953P 2012-03-27 2012-03-27
US61/615,953 2012-03-27
PCT/US2013/033703 WO2013148572A1 (en) 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement

Publications (2)

Publication Number Publication Date
JP2015522522A JP2015522522A (ja) 2015-08-06
JP2015522522A5 true JP2015522522A5 (enExample) 2016-05-19

Family

ID=49261147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503431A Pending JP2015522522A (ja) 2012-03-27 2013-03-25 刺激に誘発される薬物再発の阻止

Country Status (6)

Country Link
US (1) US20150051192A1 (enExample)
EP (1) EP2830601A4 (enExample)
JP (1) JP2015522522A (enExample)
AU (1) AU2013239995A1 (enExample)
CA (1) CA2908240A1 (enExample)
WO (1) WO2013148572A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
CN103079571A (zh) 2010-07-23 2013-05-01 德莫科斯公司 降伊波加因碱组合物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US20150258110A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence using ibogaine
WO2015163844A1 (en) * 2014-04-21 2015-10-29 Demerx, Inc. N-substituted noribogaine prodrugs
KR20220074908A (ko) * 2019-10-01 2022-06-03 마인드 메디슨, 인크. 물질 사용 장애의 치료를 위한 18-mc
US20220409628A1 (en) * 2021-06-29 2022-12-29 Mind Medicine, Inc. 18-mc for treating obesity
WO2025117491A1 (en) * 2023-12-01 2025-06-05 Kuleon Llc Azepino analogs and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211360B1 (en) * 1995-08-08 2001-04-03 Albany Medical College Ibogamine congeners
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
US20060035889A1 (en) * 2004-08-13 2006-02-16 Tedford Clark E Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
US20100040679A1 (en) * 2006-10-09 2010-02-18 Shing Yue Chang Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
KR101767273B1 (ko) * 2009-03-11 2017-08-10 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
US8785472B2 (en) * 2010-05-11 2014-07-22 National Cheng Kung University Use of dextromethorphan in treating addictive behavior or bipolar disorder

Similar Documents

Publication Publication Date Title
JP2015522522A5 (enExample)
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
JP2016515522A5 (enExample)
JP2015503422A5 (enExample)
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
IL249837B (en) Inhaler for pulmonary delivery of active agents
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
JP2017514871A5 (enExample)
MX2020004075A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
HUE040609T2 (hu) GLP-1 vegyületek orális adagolása
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
SI3069720T1 (sl) Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
HK1231381A1 (zh) 癌症组合疗法
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
ZA201704026B (en) Oral octreotide administered in combination with other therapeutic agents
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
EP2959906A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE